| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 73 | 70.4x | 17.8x | Top tier | |
Growth | 61 | 5.7% | 7.1% | Around median | |
Quality | 73 | 1.4% | 4.5% | Top tier | |
Safety | 66 | 1.5x | 2.6x | Top tier | |
Capital Return | 95 | — | 2.12% | Top tier | |
Momentum | 66 | -2.1% | 2.9% | Top tier | |
Sentiment | 38 | 4 | 3 | Bottom tier |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Pacira BioSciences operates as a pharmaceutical company focused on pain management and reducing reliance on opioids. Most of its revenue comes from EXPAREL, which is used for postsurgical pain management, alongside ZILRETTA, which is intended to treat osteoarthritis, while iovera remained in its portfolio until its sale to Zimmer Biomet was completed on July 31, 2026. In Q2 FY2026, EXPAREL sales of $147.8 million represented approximately 77% of total revenue, compared with $32.6 million for ZILRETTA and $6.8 million for iovera.
Revenue in Q2 FY2026 reached approximately $192.4 million, up 6% from the comparable period, compared with $177.4 million in Q1 FY2026. EXPAREL increased 3% from $142.9 million to $147.8 million, ZILRETTA grew 4% to $32.6 million, and iovera jumped 21% to $6.8 million. These figures reflect EXPAREL's continued dominance of the business mix, with faster but smaller-scale growth in iovera before its divestiture.
Pacira recorded gross profit of $148.2 million in Q2 FY2026, equivalent to an EDGAR-statement margin of approximately 77%, while management reported a non-GAAP gross margin of 78%, compared with 82% in the comparable period. GAAP net income was approximately $4.7 million, or $0.12 per share, with adjusted EBITDA of approximately $48.7 million. On a trailing-twelve-month basis in 2026, revenue was $746.2 million, net income was $14.6 million, and earnings per share were approximately $0.36.
Automated analysis for informational purposes only — not investment advice.
The analyst consensus on PCRX is “Neutral,” with an average price target of $29 and a range of $25 to $32; the average exceeds the upper end of the 52-week range of $27.66, while the highest target exceeds it more clearly. No reported P/E ratio is available in the data despite the company recording trailing-twelve-month earnings per share in 2026, so the stock's valuation remains heavily dependent on continued EXPAREL growth and the success of pipeline catalysts, weighed against margin pressure and the revised revenue outlook.
Figures in the text are as of 2026-09-02; the live price is shown at the top of the page.
EXPAREL is clearly the largest source, with sales of $147.8 million out of total revenue of $192.4 million in Q2 FY2026. ZILRETTA sales were approximately $32.6 million, while iovera generated approximately $6.8 million before the completion of its sale to Zimmer Biomet on July 31, 2026. This reflects a dependence on EXPAREL alone for approximately 77% of quarterly revenue.
Revenue was $192.4 million, up 6% from the comparable period, and gross profit according to EDGAR was approximately $148.2 million. The company recorded GAAP net income of $4.7 million and earnings per share of $0.12, in addition to adjusted EBITDA of approximately $48.7 million. Non-GAAP gross margin was approximately 78%, compared with 82% in the comparable period.
UnitedHealthcare's decision in July 2026 added approximately 40 million people to the scope of separate reimbursement for EXPAREL outside the surgical bundle. EXPAREL coverage now exceeds 150 million people, approaching the target of 160 million by the end of FY2026. UnitedHealthcare also placed ZILRETTA on its preferred list and eliminated prior-authorization requirements, reducing a procedural barrier to its use.
Pacira completed the sale of iovera to Zimmer Biomet on July 31, 2026, for up to $140 million. The consideration consists of $70 million upfront and an additional $70 million tied to revenue milestones, with the two companies continuing to collaborate on the spasticity program. Following the transaction, Pacira revised its FY2026 revenue range to $735–760 million and lowered its non-GAAP SG&A expense range to $310–330 million.
Pacira targets the release of results from Part A of the Phase 2 ASCENT study of PCRX-201 at the end of 2026, and this part included 49 patients divided between two doses and a control group. The company also targets the release of results from the Phase 3 ZILRETTA study in shoulder osteoarthritis and results from the registrational iovera study in spasticity before the end of 2026. In addition, enrollment in Part B of ASCENT has begun, and the company plans to begin Phase 2 development of PCRX-202 during 2026.
Macroeconomic pressures weakened some elective soft-tissue procedures during Q2 FY2026, particularly within hospitals. Soft-tissue procedures account for approximately 40% of EXPAREL volume, while orthopedic surgeries represent approximately 60%. Volume also grew approximately 4%, but revenue increased only 3% because of the vial mix and third-party group purchasing organization discounts, while NOPAIN reimbursement needs to be renewed or extended by the end of 2027.
